- N-Heterocyclic Carbene Copper(I) Complex Catalyzed Coupling of (Hetero)aryl Chlorides and Nitrogen Heterocycles: Highly Efficient Catalytic System
-
A highly efficient catalytic system for the N-arylation reactions of (hetero)aryl chlorides and nitrogen heterocycles with a copper(I) complex containing a 1,10-phenanthroline analogue N-heterocyclic carbene (NHC) has been reported. The complex was characterized by 1H NMR and 13C NMR spectroscopy and elemental analysis, and its structure was determined by single-crystal X-ray diffraction. The NHC-copper(I) complex was employed as pre-catalyst for Ullmann type N-arylation reactions of (hetero)aryl chlorides with various azoles. A variety of hindered and functionalized azoles and (hetero)aryl chlorides were transformed in good to excellent yields.
- Zhang, Mengyao,Zhang, Yingying,Zhang, Huixin,Zeng, Yongfei,Liu, Guiyan
-
p. 1252 - 1256
(2020/08/05)
-
- L -(-) -Quebrachitol as a Ligand for Selective Copper(0)-Catalyzed N-Arylation of Nitrogen-Containing Heterocycles
-
l-(-)-Quebrachitol (QCT) has been found as a ligand of copper powder for selective N-arylation of nitrogen-containing heterocycles with aryl halides. Furthermore, another potential catalytic system (copper powder/QCT/t-BuOK) was successfully adapted to unactivated aryl chlorides.
- Zhou, Qifan,Du, Fangyu,Chen, Yuanguang,Fu, Yang,Sun, Wenjiao,Wu, Ying,Chen, Guoliang
-
p. 8160 - 8167
(2019/06/28)
-
- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
Paragraph 0318
(2017/05/14)
-
- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present invention relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
Paragraph 0302
(2015/05/19)
-
- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
Paragraph 0301
(2015/08/03)
-
- THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS
-
Tetrahydroquinoline compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
- -
-
Page/Page column 95-96
(2011/06/11)
-
- SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF
-
The present invention relates to small molecule modulators of mTORCl and mT0RC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORCl, mT0RC2, and PI3K-related proteins. Novel methods of providing soluble mTORCl and mT0RC2 complexes are discussed, as well as methods of using the soluble complexes in a high- throughput manner to screen for inhibitory compounds.
- -
-
Page/Page column 93
(2010/04/30)
-
- 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS
-
The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts
- -
-
Page/Page column 50
(2010/01/12)
-
- MODULATORS OF AMYLOID BETA
-
The invention relates to compounds of formula wherein hetaryl I, hetaryl II, and R1 are as described herein. Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease.
- -
-
Page/Page column 24
(2011/07/06)
-
- BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES
-
The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.
- -
-
Page/Page column 188
(2008/06/13)
-
- CARBON-NITROGEN BOND FORMING PROCESS
-
The present invention relates to a process to create a carbon-nitrogen bond by the reaction of an aromatic compound carrying at least one electro attractive group with one nitrogenous heterocyclic type nucleophile compound. The invention aims, in particular, at a link reaction between an aromatic compound carrying at least one electro attractive group and an imidazole heterocycle type. The invention process, consisting of the reaction of an aromatic compound carrying one leaving group and at least one electro attractive group and a nitrogenous heterocyclic type nucleophile compound comprising a N-H pattern likely to substitute the leaving group, thereby creating a carbon-nitrogen bond in the presence of a copper catalyst, of a base in an organic solvent, is characterized by the fact that the said nitrogenous heterocycle reacts with an aromatic type electrophile compound carrying one leaving group (Y) chosen from bromine, chlorine or sulfonic ester and at least one electro attractive group (Z1), in the presence of a copper catalyst, of a mineral or organic base, of an extracting agent selected from aliphatic diamines, aliphatic amino alcohols and diols in a polar aprotic organic solvent with a dielectric constant less than about 20 and a basicity such that its "donor number" is less than about 25.
- -
-
Page/Page column 15
(2008/06/13)
-